fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Adjuvant pembrolizumab treatment improves survival in patients with advanced soft tissue sarcoma of the limb

Written by | 14 Nov 2024

Adding treatment with pembrolizumab to standard of care in patients with advanced soft tissue sarcoma of the limb appears to significantly improve disease-free survival, researchers reported on Nov…. read more.

Update on phase III LEAP-001 trial evaluating Keytruda (pembrolizumab) + Lenvima (lenvatinib) as first-line treatment for advanced or recurrent endometrial carcinoma – Merck Inc + Eisai

Written by | 13 Dec 2023

Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.

Keytruda (pembrolizumab) met a primary endpoint of disease-free survival in certain patients with muscle-invasive urothelial carcinoma after surgery – Merck Inc

Written by | 16 Oct 2023

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda, Merck’s anti-PD-1 therapy, met one… read more.

Immunotherapy drug did not increase surgery complications, study finds

Written by | 10 Sep 2022

A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery…. read more.

ASCO 2021: Pembrolizumab shows promise for adjuvant treatment of renal cell carcinoma

Written by | 18 Jun 2021

Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of  kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.